A potent, full efficacy dopamine D1 agonist which shows no agonist activity at peripheral D2 receptors or adrenoceptors at doses which cause maximal stimulation of D1 sites. The compound appears to be fully bioavailable in brain and exhibits profound antiparkinsonism effects in vivo.
Sold under license, US Patent 5,047,536
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 303.79. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.29 mL||16.46 mL||32.92 mL|
|5 mM||0.66 mL||3.29 mL||6.58 mL|
|10 mM||0.33 mL||1.65 mL||3.29 mL|
|50 mM||0.07 mL||0.33 mL||0.66 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Brewster et al (1990) Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J.Med.Chem. 33 1756 PMID: 1971308
Kholi et al (1993) Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. Eur.J.Pharmacol. 235 31 PMID: 8100195
Lovenberg et al (1989) Dihydrexidine, a novel selective high potency, full dopamine D-1 receptor agonist. Eur.J.Pharmacol. 166 111 PMID: 2572425
Taylor et al (1991) Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur.J.Pharmacol. 199 389 PMID: 1680717
If you know of a relevant reference for Dihydrexidine hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Dihydrexidine hydrochloride, supplier, Selective, D1-like, agonists, Dopamine, Receptors, D5, dopaminergic, D1, and, D5, Receptors, Tocris Bioscience
3 Citations for Dihydrexidine hydrochloride
Citations are publications that use Tocris products. Selected citations for Dihydrexidine hydrochloride include:
Urizar et al (2011) CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Anal Biochem 7 624 PMID: 21785426
Smith et al (2005) Dopaminergic stimulation of local protein synthesis enhances surface expression of GluR1 and synaptic transmission in hippocampal neurons. Neuron 45 765 PMID: 15748851
Parker and Kooi (2014) Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions. J Neurosci 453 42525 PMID: 24583243
Do you know of a great paper that uses Dihydrexidine hydrochloride from Tocris? If so please let us know.
Literature in this Area
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.